RBC Capital Maintains Outperform on Versigent, Raises Price Target to $53

RBC Capital analyst Tom Narayan has maintained an 'Outperform' rating on Versigent (NYSE: VGNT) and increased the price target from $52 to $53. This adjustment reflects a positive outlook on the company's performance.